<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01709370</url>
  </required_header>
  <id_info>
    <org_study_id>OOTR-N007/LET-CDK</org_study_id>
    <nct_id>NCT01709370</nct_id>
  </id_info>
  <brief_title>Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women</brief_title>
  <official_title>Phase II Neoadjuvant Study of Letrozole in Combination With PD0332991 (Oral CDK 4/6 Inhibitor) for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organisation for Oncology and Translational Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Organisation for Oncology and Translational Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study evaluating the efficacy and safety of the pre-operative use of
      letrozole plus PD 0332991 (combination therapy)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rates</measure>
    <time_frame>Every 4 weeks before surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Continuous during the study, up to 28 days after the last treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pathologic response rates</measure>
    <time_frame>At time of definitive surgery</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>ER Positive, HER2 Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole plus PD 0332991</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole, PD 0332991</intervention_name>
    <arm_group_label>Letrozole plus PD 0332991</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Primary tumor greater than 2 cm in diameter

          -  Histologically proven invasive breast cancer

          -  Positive estrogen receptor

          -  Negative HER-2 receptor

          -  ECOG performance status ≤ 1 or Karnofsky performance status ≥ 70%

          -  Laboratory values must be follows:

        Absolute neutrophil count ≥ 1,500/mm3; Platelets ≥ 100,000/mm3; Hemoglobin ≥ 9 g/dL;
        Bilirubin ≤ 1.5 × institutional upper limit of normal (ULN); Serum Creatinine ≤ 1.5 × ULN;
        Alkaline phosphatase ≤ 2 × ULN; AST and ALT ≤ 2 × ULN; Normal finding of ECG - QTc ≤ 470
        msec (based on the mean value of the triplicate ECGs); Left ventricular ejection fraction
        (LVEF) ≥ 60%.

          -  Able to give written informed consent form

          -  Able to follow prescription instructions reasonably well

        Exclusion Criteria:

          -  Male

          -  Severe psychiatric disorder

          -  Prior history of other malignancy within 5 years of study entry, aside from basal cell
             carcinoma or the skin or carcinoma-in-situ of the uterine cervix

          -  Locally advanced breast cancer (T3N1 or Any T4 or Any N2, N3), or distant metastasis

          -  Multifocal or multicentric breast cancer except that the largest lesion is greater
             than 2cm

          -  Major surgery within 3 weeks of first study treatment

          -  Current use or anticipated need for:

        Food or drugs that are known strong CYP3A4 inhibitors; drugs that are known strong CYP3A4
        inducers

          -  Severe cardiovascular diseases in the previous 6 months

          -  Active inflammatory bowel disease or chronic diarrhea

          -  Renal Impairment

          -  Poor adrenal function

          -  Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function)

          -  Known human immunodeficiency virus infection

          -  Known hypersensitivity to anti-aromatase drugs or any cell cycle inhibitor

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Louis Chow, MD</last_name>
    <phone>(852)28610286</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Unimed Medical Institute</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Chow, MD</last_name>
      <phone>(852)28610286</phone>
    </contact>
    <investigator>
      <last_name>Louis Chow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2012</study_first_submitted>
  <study_first_submitted_qc>October 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2012</study_first_posted>
  <last_update_submitted>December 29, 2013</last_update_submitted>
  <last_update_submitted_qc>December 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

